![Michael Wolff Jensen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Wolff Jensen
General Counsel at ASCENDIS PHARMA A/S
Net worth: 267 347 $ as of 2024-08-30
Profile
Mr. Michael Wolff Jensen is a Chairman at Vicore Pharma Holding AB, a Chief Executive Officer at Miwo Invest ApS, a Chairman at Xspray Pharma AB, a Chairman at Ascendis Pharma Endocrinology Division A/S, a Chairman, Chief Legal Officer & Senior VP at Ascendis Pharma A/S, a Chairman at Ascendis Pharma Bone Diseases A/S and a Chairman at Ascendis Pharma Growth Disorders AS. He is on the Board of Directors at Visen Pharmaceuticals (Shanghai) Co. Ltd. Mr. Jensen was previously employed as a Chairman by Eurocine Vaccines AB, a Head-France Partnerships by DONG Energy A/S, a Chief Financial Officer & Executive Vice President by LifeCycle Pharma A/S, a Chief Financial Officer & Senior Vice President by Genmab A/S, a President & Chief Executive Officer by EMF Industries A/S, a Chairman by MWJ Invest AB, a Chairman by Paradis A/S, and a Chairman by Vanx ApS. He also served on the board at Azanta A/S. He received his graduate degree from the University of Copenhagen.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ASCENDIS PHARMA A/S
0.00% | 2023-12-30 | 1,931 ( 0.00% ) | 267 347 $ | 2024-08-30 |
Latest news about Michael Wolff Jensen
Michael Wolff Jensen active positions
| Companies | Position | Start |
|---|---|---|
| ASCENDIS PHARMA A/S | General Counsel | 2013-05-31 |
Miwo Invest ApS
 Miwo Invest ApS Miscellaneous Commercial ServicesCommercial Services Miwo Invest ApS owns and manages shares and ownership interests in other companies, as well as run consulting business within strategic business development, business strategy, financing, and investment. The company was founded by Michael Wolff Jensen on January 28, 2014 and is headquartered in Charlottenlund, Denmark. | Chief Executive Officer | 2014-01-27 |
| Ascendis Pharma Ophthalmology Division A/S | Chairman | - |
| Ascendis Pharma, Inc. | Director/Board Member | - |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Chairman | 2021-01-07 |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Chairman | - |
| Ascendis Pharma Growth Disorders AS | Chairman | - |
| Ascendis Pharma Bone Diseases A/S | Chairman | - |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Director/Board Member | 2021-04-30 |
| ░░░░░░░░ ░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Former positions of Michael Wolff Jensen
| Companies | Position | End |
|---|---|---|
| ░░░░░░ ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Michael Wolff Jensen
| University of Copenhagen | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| ORSTED A/S | Utilities |
| GENMAB A/S | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| VICORE PHARMA HOLDING AB | Health Technology |
| Private companies | 17 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
| EMF Industries A/S | |
| Paradis A/S | |
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | Health Technology |
Eurocine Vaccines AB
 Eurocine Vaccines AB Pharmaceuticals: MajorHealth Technology Eurocine Vaccines AB engages in the research and development of nasal influenza vaccine for children and adult. Its technology, Endocine used to develop a patent protected nasal influenza vaccine for children. The company was founded in 1999 and is headquartered in Solna, Sweden. | Health Technology |
| MWJ Invest AB | |
| Vanx ApS | |
Miwo Invest ApS
Miwo Invest ApS Miscellaneous Commercial ServicesCommercial Services Miwo Invest ApS owns and manages shares and ownership interests in other companies, as well as run consulting business within strategic business development, business strategy, financing, and investment. The company was founded by Michael Wolff Jensen on January 28, 2014 and is headquartered in Charlottenlund, Denmark. | Commercial Services |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Health Technology |
| Ascendis Pharma Bone Diseases A/S | |
| Ascendis Pharma Growth Disorders AS | |
Vicore Pharma AB
Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Health Technology |
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
| Ascendis Pharma, Inc. | |
| Ascendis Pharma Ophthalmology Division A/S | |
| Ascendis Pharma Oncology Division A/S |
- Stock Market
- Insiders
- Michael Wolff Jensen
